5 Best Biotech Stocks To Buy Now

4. Amgen Inc. (NASDAQ:AMGN)

Number of Hedge Fund Holders: 55

Amgen Inc. (NASDAQ:AMGN) is an American multinational biotech company committed to developing innovative human therapeutics. The company’s focus therapy area is serious diseases including but not limited to, oncology, cardiovascular diseases, neurology, and nephrology. 

Owing to its diverse portfolio of therapy areas, the firm has a market cap of close to $127.51 billion and estimated annual revenue near $26.16 billion. As of August 26, 2022, Two Sigma Advisors is the largest stakeholder in our database in Amgen Inc. (NASDAQ:AMGN) with more than $1.6 billion shares worth $404.29 million.

ClearBridge Investments mentioned Amgen Inc. (NASDAQ:AMGN) in its Q3 2021 investor letter. Here is what the firm has to say:

“In health care, Amgen, a biotechnology company, has endured several pipeline setbacks recently, including a slow transition of its Lumakras treatment into first-line lung cancer, a slower than expected development of its treatment for myeloma as well as the company’s asthma treatment Tezepelumab missing its primary endpoint in a Phase III study. We remain positive on the stock, with Amgen’s investments in biosimilars and its pipeline part of our long-term thesis.”